Targeting Tumor Microenvironment in Cancer: An Impact on Therapeutic Efficacy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 2670

Special Issue Editor


E-Mail Website
Guest Editor
1. Drug Development Program, Kansas City VA Medical Center, Kansas City, MO 64128, USA
2. Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA
Interests: breast cancer; pancreatic cancer; non-small-cell lung cancer; neuroinflammation; NLRP3; microRNA; inflammasome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The tumor microenvironment (TME) is defined as a complex ecosystem of cellular and non-cellular components where cancer grows. Cellular components include not only cancer cells but also many other types of cells, including cancer-associated stromal and infiltrating immune cells that play critical roles in cancer biology. The non-cellular components comprise signaling molecules and proteins of the extracellular matrix (ECM). Cancer cells influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing immune tolerance where the stromal and immune cells help cancer cells to escape immune recognition, providing a pro-tumorigenic environment to develop drug resistance in order to metastasize and exhibit even more malignant behaviors. By targeting the TME, it is possible to disrupt the interactions between tumor cells and other cells in the microenvironment, preventing tumor growth and metastasis. We invite authors to contribute cutting-edge studies to this Special Issue, entitled “Targeting Tumor Microenvironment in Cancer: An Impact on Therapeutic Efficacy”, to further highlight the challenges and opportunities associated with TME-targeted therapy.

In this Special Issue, original research articles and reviews are welcome to be submitted. Research areas may include, but are not limited to, the following:

  • VEGF/VEGFR-targeted therapy;
  • Immune checkpoint blockade;
  • Recent advances and challenges in tumor microenvironment targeting;
  • Targeting cancer stem cells;
  • Tumor microenvironment and its therapeutic implications.
  • Microbiome

We look forward to receiving your contributions.

Dr. Inamul Haque
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • VEGF/VEGFR-targeted therapy
  • immune checkpoint blockade
  • recent advances and challenges in tumor microenvironment targeting
  • targeting cancer stem cells
  • tumor microenvironment and its therapeutic implications
  • microbiome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

29 pages, 1508 KiB  
Review
Blocking Tumoral Angiogenesis VEGF/VEGFR Pathway: Bevacizumab—20 Years of Therapeutic Success and Controversy
by Elena Chitoran, Vlad Rotaru, Daniela-Cristina Stefan, Giuseppe Gullo and Laurentiu Simion
Cancers 2025, 17(7), 1126; https://doi.org/10.3390/cancers17071126 - 27 Mar 2025
Viewed by 640
Abstract
The “angiogenesis switch”—defined as the active process by which solid tumors develop their own circulation—plays an important role in both tumoral growth and propagation. As the malignant tumor grows and reaches a critical size, the metabolic needs as a function of an ever-increasing [...] Read more.
The “angiogenesis switch”—defined as the active process by which solid tumors develop their own circulation—plays an important role in both tumoral growth and propagation. As the malignant tumor grows and reaches a critical size, the metabolic needs as a function of an ever-increasing distance to the nearest emergent blood vessel, can no longer be covered by the microenvironment of the peritumoral tissue. Although a relatively discrete process, the “angiogenic switch” acts as a limiting stage of tumoral development present from the avascular hyperplasia phase to the vascularized neoplastic phase, providing support for tumor expansion and metastasis. Over time, research has focused on blocking the angiogenetic pathways (such as VEGF/VEGFR signaling axis) leading to the development of targeted therapeutic agents such as Bevacizumab. Objectives: We conducted a review of the molecular principles of tumoral angiogenesis and we tried to follow the history of Bevacizumab from its first approval for human usage 20 years ago to current days, focusing on the impact this agent had in solid tumor therapy. A comprehensive review of clinical trials pertaining to Bevacizumab (from the era of the preclinic trials leading to approval for human usage, to the more recent randomized trial focusing on combination targeted therapy) further details the role of this drug. We aimed to establish if this ancient drug continues to have a place in modern oncology. Conclusions: Bevacizumab, one of the first drugs targeting tumoral microenvironment, remains one of the most important oncologic agents blocking the VEGF/VEGFR angiogenic pathway. otherwise, history of 20 years marked by numerous controversies (ranging from methodological errors of clinical trials to withdrawal of approval for human usage in breast cancer patients, from discussions about severe side effects to resistance to therapy and limited efficacity), Bevacizumab continues to provide an optimal therapeutic option for many solid tumors that previously had little to no means of treatment, improving otherwise bleak outcomes. Even in the era of personalized precision oncology, Bevacizumab continues to be a key element in many therapeutic regimens both as monotherapy and in combination with newer targeted agents. Full article
Show Figures

Figure 1

32 pages, 1362 KiB  
Review
Unveiling the Interplay Between the Human Microbiome and Gastric Cancer: A Review of the Complex Relationships and Therapeutic Avenues
by Jenan Al-Matouq, Hawra Al-Ghafli, Noura N. Alibrahim, Nida Alsaffar, Zaheda Radwan and Mohammad Daud Ali
Cancers 2025, 17(2), 226; https://doi.org/10.3390/cancers17020226 - 12 Jan 2025
Viewed by 1115
Abstract
The human microbiota plays a crucial role in maintaining overall health and well-being. The gut microbiota has been implicated in developing and progressing various diseases, including cancer. This review highlights the related mechanisms and the compositions that influence cancer pathogenesis with a highlight [...] Read more.
The human microbiota plays a crucial role in maintaining overall health and well-being. The gut microbiota has been implicated in developing and progressing various diseases, including cancer. This review highlights the related mechanisms and the compositions that influence cancer pathogenesis with a highlight on gastric cancer. We provide a comprehensive overview of the mechanisms by which the microbiome influences cancer development, progression, and response to treatment, with a focus on identifying potential biomarkers for early detection, prevention strategies, and novel therapeutic interventions that leverage microbiome modulation. This comprehensive review can guide future research and clinical practices in understanding and harnessing the microbiome to optimize gastric cancer therapies. Full article
Show Figures

Figure 1

Back to TopTop